Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression

Simon Arnett Jones; Gareth Wyn Jones; Anwen Sian Williams; Mari Ann Nowell

Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression

Simon Arnett Jones, Gareth Wyn Jones, Anwen Sian Williams, Mari Ann Nowell

School of Cellular and Molecular Medicine

Research output: Contribution to journal › Article (Academic Journal) › peer-review

Abstract

The humanized anti-interleukin (IL)-6 receptor antibody Tocilizumab is currently in Phase III clinical trials for use in autoimmune conditions such as rheumatoid arthritis and Crohn's disease. However do we fully appreciate the regulation of IL-6 responses in vivo, and understand the wider implications of IL-6 bioactivity in general physiology and inflammation? In the context of this review we will explore how IL-6 affects arthritis progression, and discuss the inflammatory mechanism governing IL-6 responsiveness. Specific attention will be given to the role of the soluble IL-6 receptor and we will discuss the merit of selectively targeting this soluble receptor as an alternative therapeutic strategy for clinically blocking IL-6 involvement in disease.

Original language	Undefined/Unknown
Pages (from-to)	235-246
Number of pages	12
Journal	Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry
Volume	8
Issue number	3
Publication status	Published - 1 Jan 2008

Keywords

Cytokines, receptors, chemokines, inflammation, arthritis, leukocytes, gp130, tocilizumab

Access to Document

http://orca.cf.ac.uk/17548/

Handle.net

Persistent link

Cite this

@article{0c508148e87a43b3b794c557008ff9a2,

title = "Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression",

abstract = "The humanized anti-interleukin (IL)-6 receptor antibody Tocilizumab is currently in Phase III clinical trials for use in autoimmune conditions such as rheumatoid arthritis and Crohn's disease. However do we fully appreciate the regulation of IL-6 responses in vivo, and understand the wider implications of IL-6 bioactivity in general physiology and inflammation? In the context of this review we will explore how IL-6 affects arthritis progression, and discuss the inflammatory mechanism governing IL-6 responsiveness. Specific attention will be given to the role of the soluble IL-6 receptor and we will discuss the merit of selectively targeting this soluble receptor as an alternative therapeutic strategy for clinically blocking IL-6 involvement in disease.",

keywords = "Cytokines, receptors, chemokines, inflammation, arthritis, leukocytes, gp130, tocilizumab",

author = "Jones, {Simon Arnett} and Jones, {Gareth Wyn} and Williams, {Anwen Sian} and Nowell, {Mari Ann}",

year = "2008",

month = jan,

day = "1",

language = "Undefined/Unknown",

volume = "8",

pages = "235--246",

journal = "Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry",

issn = "1871-5222",

publisher = "Bentham Science Publishers",

number = "3",

}

Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression. / Jones, Simon Arnett; Jones, Gareth Wyn; Williams, Anwen Sian et al.

In: Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, Vol. 8, No. 3, 01.01.2008, p. 235-246.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression

AU - Jones, Simon Arnett

AU - Jones, Gareth Wyn

AU - Williams, Anwen Sian

AU - Nowell, Mari Ann

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The humanized anti-interleukin (IL)-6 receptor antibody Tocilizumab is currently in Phase III clinical trials for use in autoimmune conditions such as rheumatoid arthritis and Crohn's disease. However do we fully appreciate the regulation of IL-6 responses in vivo, and understand the wider implications of IL-6 bioactivity in general physiology and inflammation? In the context of this review we will explore how IL-6 affects arthritis progression, and discuss the inflammatory mechanism governing IL-6 responsiveness. Specific attention will be given to the role of the soluble IL-6 receptor and we will discuss the merit of selectively targeting this soluble receptor as an alternative therapeutic strategy for clinically blocking IL-6 involvement in disease.

AB - The humanized anti-interleukin (IL)-6 receptor antibody Tocilizumab is currently in Phase III clinical trials for use in autoimmune conditions such as rheumatoid arthritis and Crohn's disease. However do we fully appreciate the regulation of IL-6 responses in vivo, and understand the wider implications of IL-6 bioactivity in general physiology and inflammation? In the context of this review we will explore how IL-6 affects arthritis progression, and discuss the inflammatory mechanism governing IL-6 responsiveness. Specific attention will be given to the role of the soluble IL-6 receptor and we will discuss the merit of selectively targeting this soluble receptor as an alternative therapeutic strategy for clinically blocking IL-6 involvement in disease.

KW - Cytokines, receptors, chemokines, inflammation, arthritis, leukocytes, gp130, tocilizumab

M3 - Article (Academic Journal)

VL - 8

SP - 235

EP - 246

JO - Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

JF - Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

SN - 1871-5222

IS - 3

ER -